Class summary at a glance.

Every drug in the Antiparasitic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $19.9Mcombined across class
Total Rx claims: 127K84K unique beneficiaries
Generic mfrs (active): 9across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ivermectin

Brand: SOOLANTRA · 127K Part D claims (CY24) · 84K beneficiaries · First FDA approval: 1996-11-22

9 generic mfrs 350 plans require PA

Low NADAC$2.42

→

Avg plan cost$4.20

Part D spend $19.9M 2× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.